First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• The number of patients with adverse events

  Measured over: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

• The number of patients with serious adverse events

  Measured over: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

• The number of patients with adverse events of special interest

  Measured over: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

• The number of AEs leading to discontinuation of AZD9793

  Measured over: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

• The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only]

  Measured over: From date of first dose of study drug until the end of DLT evaluation period (up to 21, 28 or 35 days depending on dose regimen)

• Objective Response Rate (ORR) [Part B Dose Expansion only]

  Measured over: From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)

Changes Tremor has spotted